These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Role of the 5-HT Preller KH; Schilbach L; Pokorny T; Flemming J; Seifritz E; Vollenweider FX J Neurosci; 2018 Apr; 38(14):3603-3611. PubMed ID: 29555857 [TBL] [Abstract][Full Text] [Related]
25. Hyperthermic effects of D-lysergic acid diethylamide (LSD) and its derivatives in rabbits and rats. Hashimoto H; Hayashi M; Nakahara Y; Niwaguchi T; Ishii H Arch Int Pharmacodyn Ther; 1977 Aug; 228(2):314-21. PubMed ID: 303504 [TBL] [Abstract][Full Text] [Related]
26. From Psychiatry to Flower Power and Back Again: The Amazing Story of Lysergic Acid Diethylamide. Mucke HA Assay Drug Dev Technol; 2016 Jul; 14(5):276-281. PubMed ID: 27392130 [TBL] [Abstract][Full Text] [Related]
27. Serotonergic and dopaminergic distinctions in the behavioral pharmacology of (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Schindler EA; Dave KD; Smolock EM; Aloyo VJ; Harvey JA Pharmacol Biochem Behav; 2012 Mar; 101(1):69-76. PubMed ID: 22197710 [TBL] [Abstract][Full Text] [Related]
28. Lysergic acid diethylamide-induced Fos expression in rat brain: role of serotonin-2A receptors. Gresch PJ; Strickland LV; Sanders-Bush E Neuroscience; 2002; 114(3):707-13. PubMed ID: 12220572 [TBL] [Abstract][Full Text] [Related]
29. Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD). Brandt SD; Kavanagh PV; Westphal F; Stratford A; Elliott SP; Hoang K; Wallach J; Halberstadt AL Drug Test Anal; 2016 Sep; 8(9):891-902. PubMed ID: 26456305 [TBL] [Abstract][Full Text] [Related]
30. Behavioral tolerance to lysergic acid diethylamide is associated with reduced serotonin-2A receptor signaling in rat cortex. Gresch PJ; Smith RL; Barrett RJ; Sanders-Bush E Neuropsychopharmacology; 2005 Sep; 30(9):1693-702. PubMed ID: 15756304 [TBL] [Abstract][Full Text] [Related]
31. Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor. Preller KH; Burt JB; Ji JL; Schleifer CH; Adkinson BD; Stämpfli P; Seifritz E; Repovs G; Krystal JH; Murray JD; Vollenweider FX; Anticevic A Elife; 2018 Oct; 7():. PubMed ID: 30355445 [TBL] [Abstract][Full Text] [Related]
32. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders. Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717 [TBL] [Abstract][Full Text] [Related]
33. Effects of repeated administration of the monoamine oxidase inhibitor phenelzine on the discriminability of d-lysergic acid diethylamide (LSD) and 1-(m-trifluoromethylphenyl) piperazine (TFMPP). Cunningham KA; Carroll BA; Appel JB Psychopharmacology (Berl); 1986; 89(1):134-5. PubMed ID: 3090587 [TBL] [Abstract][Full Text] [Related]
34. Return of the lysergamides. Part V: Analytical and behavioural characterization of 1-butanoyl-d-lysergic acid diethylamide (1B-LSD). Brandt SD; Kavanagh PV; Westphal F; Stratford A; Elliott SP; Dowling G; Wallach J; Halberstadt AL Drug Test Anal; 2019 Aug; 11(8):1122-1133. PubMed ID: 31083768 [TBL] [Abstract][Full Text] [Related]
35. Neural correlates of the LSD experience revealed by multimodal neuroimaging. Carhart-Harris RL; Muthukumaraswamy S; Roseman L; Kaelen M; Droog W; Murphy K; Tagliazucchi E; Schenberg EE; Nest T; Orban C; Leech R; Williams LT; Williams TM; Bolstridge M; Sessa B; McGonigle J; Sereno MI; Nichols D; Hellyer PJ; Hobden P; Evans J; Singh KD; Wise RG; Curran HV; Feilding A; Nutt DJ Proc Natl Acad Sci U S A; 2016 Apr; 113(17):4853-8. PubMed ID: 27071089 [TBL] [Abstract][Full Text] [Related]
36. [Experimental and clinical pharmacological aspects of the hallucinogen LSD-25]. Nisticò G Clin Ter; 1968 Oct; 47(2):119-60. PubMed ID: 4883264 [No Abstract] [Full Text] [Related]
38. LSD, madness and healing: Mystical experiences as possible link between psychosis model and therapy model. Wießner I; Falchi M; Palhano-Fontes F; Feilding A; Ribeiro S; Tófoli LF Psychol Med; 2023 Mar; 53(4):1151-1165. PubMed ID: 34253268 [TBL] [Abstract][Full Text] [Related]
39. Cross tolerance between D-2-brom-lysergic acid diethylamide (BOL-148) and the D-diethylamide of lysergic acid (LSD-25). ISBELL H; MINER EJ; LOGAN CR Psychopharmacologia; 1959 Nov; 1():109-16. PubMed ID: 14405871 [No Abstract] [Full Text] [Related]
40. Addressing the Current Knowledge and Gaps in Research Surrounding Lysergic Acid Diethylamide (LSD), Psilocybin, and Psilocin in Rodent Models. Ezeaka UC; Kim HJJ; Laprairie RB Curr Top Med Chem; 2023; 23(23):2232-2241. PubMed ID: 37409550 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]